Vancomycin AUC Monitoring in MRSA Bacteremia
A 55-year-old man (weight 85 kg, height 175 cm, SCr 1.4 mg/dL) with MRSA bacteremia is on vancomycin 1 g IV q12h. After 3 doses, a trough (pre-dose) is 18 mg/L and a peak (2 h post-infusion) is 32 mg/L. The infectious diseases team asks whether to continue, and the pharmacist notes the institution now recommends AUC-guided dosing (target AUC24/MIC 400–600) rather than trough-only monitoring.
1. Estimate whether this regimen achieves the target AUC24/MIC, and interpret the trough.
Read the worked answer
Using a simplified first-order estimate: for vancomycin, AUC24 ≈ trough-based or trapezoidal estimation; a practical approximation is AUC24 ≈ (trough + peak)/2 × 24 only if levels are stable, which they are not yet. Better: use the Bayesian/linear-log trapezoid method with the two levels. Rough check: with trough 18 and peak 32, the average concentration over the interval is roughly (18+32)/2 ≈ 25 mg/L; AUC over 24 h ≈ 25 × 24 ≈ 600 mg·h/L, at the upper end of the 400–600 target (assuming MIC 1 mg/L). A trough of 18 mg/L is above the traditional 15–20 target upper bound and raises nephrotoxicity concern, especially with an AUC near 600. The regimen is likely at or above target; do not simply continue without AUC calculation - a formal AUC (Bayesian) is needed.
2. Recommend a dose adjustment and monitoring plan based on AUC-guided dosing.
Read the worked answer
Target AUC24/MIC 400–600 (MIC 1 mg/L for MRSA). If the estimated AUC is ~600, reduce exposure: either decrease the dose to 750–1000 mg q12h or extend the interval to q24h depending on the AUC estimate, then recheck levels. Obtain a pre-dose trough and a post-distributional peak (or two levels for Bayesian software) after 3–4 doses of the new regimen. Monitor SCr and BUN every 24–48 h, urine output, and hearing/renal function. Because he has MRSA bacteremia, ensure source control (remove lines, echo if indicated) and consider adding ceftaroline or daptomycin if persistent bacteremia; do not under-dose. Reassess AUC after each change.
3. The patient's SCr rises to 2.2 mg/dL. How does this change your approach?
Read the worked answer
Rising SCr indicates vancomycin-associated nephrotoxicity (or sepsis/AKI). Recalculate CrCl (Cockcroft-Gault: ((140−55)×85)/(72×2.2) ≈ 45 mL/min), which is markedly reduced. Hold the next dose, obtain a trough/level, and adjust to renal function - e.g., 750 mg q24h or dose by AUC targeting 400–600 with extended interval. Avoid concomitant nephrotoxins (NSAIDs, aminoglycosides, contrast, piperacillin-tazobactam if avoidable). Monitor SCr daily, consider alternative MRSA therapy (daptomycin, linezolid) if AKI worsens or bacteremia persists, and ensure fluid/hemodynamic status is optimized. Document the AKI and communicate with the ID team.